Clinical Trials on Leukemia, Chronic Myelogenous

Total 36888 results

University of Bonn
Pfizer; RWTH Aachen University; Ludwig-Maximilians - University of Munich; Heidelberg... and other collaborators

Unknown

Phase II Study Testing the Tolerability and the Efficacy of Bosutinib in Chronic Phase CML Patients (BODO)

Chronic Myelogenous Leukaemia

Germany
Versailles Hospital

Recruiting

PONAZA : A COMBINATION OF PONATINIB AND 5-AZACITIDINE IN CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE OR IN MYELOID BLAST CRISIS (PONAZA)

CHRONIC MYELOGENOUS LEUKAEMIA IN ACCELERATED PHASE | CHRONIC MYELOGENOUS LEUKAEMIA IN MYELOID BLAST CRISIS

France
National Cancer Institute (NCI)

Completed

Homoharringtonine in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Terminated

Dasatinib and Cyclosporine in Treating Patients With Chronic Myelogenous Leukemia Refractory or Intolerant to Imatinib Mesylate

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Oblimersen and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Completed

Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Childhood Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
National Cancer Institute (NCI)

Terminated

Temsirolimus and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
National Cancer Institute (NCI)

Completed

Homoharringtonine Plus Low-Dose Cytarabine in Treating Patients With Newly Diagnosed Chronic Myelogenous Leukemia in Chronic Phase

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
M.D. Anderson Cancer Center
Novartis

Completed

Phase II Nilotinib With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia (CML)

Leukemia, Myelogenous, Chronic

United States
The University of Hong Kong

Unknown

Cessation of Tyrosine Kinase Inhibitors in Patients With Chronic-phase Chronic Myelogenous Leukaemia

Leukemia, Myelogenous, Chronic Phase

Hong Kong
National Cancer Institute (NCI)

Completed

Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
Assiut University

Unknown

Chronic Myloid Leukemic Patients Treated With Tyrosine Kinase Inhibitor

Chronic Phase Chronic Myelogenous Leukemia
Thomas Jefferson University

Completed

A Mobile Intervention (txt4TKI) for the Improvement of Tyrosine Kinase Inhibitor Management in Patients With Chronic Myeloid Leukemia

Chronic Phase Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive

United States
Hoffmann-La Roche

Completed

An Extension Study of RO5045337 in Participants Participating in Previous Roche-sponsored Cancer Studies

Myelogenous Leukemia, Chronic, Neoplasms, Myelogenous Leukemia, Acute

United States, France, Canada
Hospices Civils de Lyon

Completed

Nilotinib + Pegylated Interferon Alpha 2a for Untreated Chronic Phase Chronic Myelogenous Leukemia (NILOPEG)

Chronic Myelogenous Leukemia

France
Children's Oncology Group
Pfizer; Erasmus Medical Center; Dutch Childhood Oncology Group; Innovative Therapies...

Active, not recruiting

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Blastic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome Positive CML

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Terminated

Axitinib and Bosutinib in Treating Patients With Chronic, Accelerated, or Blastic Phase Chronic Myeloid Leukemia

Accelerated Phase Chronic Myelogenous Leukemia (CML) | Blast Phase Chronic Myelogenous Leukemia (CML) | Chronic Phase Phase Chronic Myelogenous Leukemia (CML) | Philadelphia Chromosome Positive (Ph+) Phase Chronic Myelogenous Leukemia (CML)

United States
University of California, San Francisco
American Society of Hematology

Completed

A Distress Reduction Intervention for Patients With BCR-ABL-Negative MPNs or CML on Tyrosine Kinase Inhibitors

Chronic Myeloid Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Myeloproliferative Neoplasm

United States
Medical College of Wisconsin
H. Jean Khoury Cure CML Consortium

Recruiting

Protocol Number: HJKC3-0003. Treatment Free Remission After Combination Therapy With Asciminib (ABL001) Plus Tyrosine Kinase Inhibitors (TKI) in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients Who Relapsed After a Prior Attempt at TKI Discontinuation

Chronic Phase Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Withdrawn

Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment

Leukemia
M.D. Anderson Cancer Center

Completed

Late Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Kanto CML Study Group

Unknown

Dasatinib for Patients Achieving Complete Molecular Response for Cure D-NewS Trial

Myelogenous Leukemia, Chronic, Chronic Phase

Japan
Incyte Biosciences UK

Completed

CALLS: CML and Ph+ALL Low Level Mutation Prevalence Survey

Accelerated Phase Chronic Myelogenous Leukemia | Chronic Phase Chronic Myelogenous Leukemia | Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia | Blastic Phase Chronic Myelogenous Leukemia

United Kingdom, Ireland
National Cancer Institute (NCI)

Completed

Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Unspecified Childhood Solid Tumor, Protocol Specific | Accelerated Phase Chronic Myelogenous Leukemia | Childhood Chronic Myelogenous Leukemia | Recurrent Childhood Acute Lymphoblastic Leukemia | Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic... and other conditions

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia

Leukemia

United States
Novartis Pharmaceuticals

Completed

Everolimus and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia Who Are Not in Complete Cytogenetic Remission After Previous Imatinib Mesylate

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Immunex Corporation

Withdrawn

Therapy of Relapsed AML With Chemotherapy and Dendritic Cell Activated Lymphocytes

Acute Myelogenous Leukemia | Chronic Myelogenous Leukemia
M.D. Anderson Cancer Center
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Completed

Zarnestra and Gleevec in Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myeloid, Chronic

United States
Pfizer

Completed

A Multicenter Phase 3, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Myelogenous, Chronic, Breakpoint Cluster Region-Abelson Proto-oncogene (BCR-ABL) Positive

France, United States, Canada, Spain, Czechia, Singapore, Thailand, Denmark, Norway, Korea, Republic of, Finland, Hungary, Sweden, Netherlands, Italy, Germany, Ukraine, South Africa, Taiwan, Australia, Belgium, Israel, Mexico, Poland, S... and more
Pfizer

Completed

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia, Chronic Myelogenous

Japan
Heidelberg University

Completed

Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Leukemia

Germany, Switzerland
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate

Leukemia

United States
Novartis

Completed

Efficacy, Safety and Long-term Prognosis of Imatinib in Patients Newly Diagnosed With Chronic Myelogenous Leukemia (Chronic Phase)

Chronic Myelogenous Leukemia in Chronic Phase
Merck Sharp & Dohme LLC

Terminated

Polyethylene Glycol Interferon Alfa-2b (PEG Intron) Versus Interferon Alfa-2b (INTRON^® A) in the Treatment of Newly Diagnosed Chronic Myelogenous Leukemia (CML) (C98026)

Chronic Myelogenous Leukemia
Astex Pharmaceuticals, Inc.

Completed

Phase II Trial of Decitabine in Patients With Chronic Myelogenous Leukemia Chronic Phase Who Are Refractory to Imatinib Mesylate (Gleevec)

Chronic Myelogenous Leukemia

United States, Canada
M.D. Anderson Cancer Center

Active, not recruiting

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Acute Myeloid Leukemia | Recurrent Acute Myeloid Leukemia | Refractory Acute Myeloid Leukemia | Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Accelerated Phase...

United States
Jonsson Comprehensive Cancer Center
Bristol-Myers Squibb

Completed

BMS-354825 in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Is Resistant to Imatinib Mesylate

Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Chemotherapy and Biological Therapy in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia

Leukemia

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

BMS-354825 or Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Did Not Respond to Previous Imatinib Mesylate

Leukemia

United States
National Cancer Institute (NCI)

Completed

STI571 Plus Cytarabine in Treating Patients With Chronic Myelogenous Leukemia

Relapsing Chronic Myelogenous Leukemia | Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Blastic Phase Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia

Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive | Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia

United States
M.D. Anderson Cancer Center
Wyeth is now a wholly owned subsidiary of Pfizer

Completed

Interleukin 11, Thrombocytopenia, Imatinib in Chronic Myelogenous Leukemia (CML) Patients

Leukemia | Chronic Myeloid Leukemia | Chronic Myelogenous Leukemia

United States
Bristol-Myers Squibb

Completed

Study of Dasatinib (BMS-354825) in Patients With Accelerated Phase Chronic Myeloid Leukemia

Chronic Myelogenous Leukemia

Netherlands, United States, Italy, Argentina, Brazil, Canada, Germany, Peru, Singapore, Taiwan, United Kingdom, France, Korea, Republic of, Philippines, Sweden, Thailand, Finland, Australia, Israel, Belgium, Denmark, Norway, Switzer...
M.D. Anderson Cancer Center

Completed

Study of Lonafarnib and Gleevec in Chronic Myelogenous Leukemia

Chronic Myelogenous Leukemia

United States
Beth Israel Deaconess Medical Center
National Institutes of Health (NIH); Teva Pharmaceuticals USA

Terminated

Arsenic Trioxide and Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia (CML)

Chronic Myelogenous Leukemia

United States
Novartis Pharmaceuticals

Completed

Nilotinib Versus Standard Imatinib (400/600 mg Every Day (QD)) Comparing the Kinetics of Complete Molecular Response for Chronic Myelogenous Leukemia in Chronic Phase (CML-CP) Pts With Evidence of Persistent Leukemia by Real-time Quantitative Polymerase Chain Reaction (RQ-PCR)

CHRONIC MYELOGENOUS LEUKEMIA

Canada, Australia, Spain, Argentina, France, Brazil
Kerman University of Medical Sciences

Terminated

Population Pharmacokinetics of Imatinib in CML Patients in Iran

Chronic Myelogenous Leukemia

Iran, Islamic Republic of
Novartis Pharmaceuticals

Completed

Randomized Phase Lll Study of Imatinib Dose Optimization vs Nilotinib in CML Patients With Suboptimal Response to Imatinib (LASOR)

Chronic Myelogenous Leukemia

China, Argentina, Russian Federation, Germany, Guatemala, Panama, Colombia, Mexico, Brazil, India, Poland, Venezuela
University of Massachusetts, Worcester

Terminated

Safety of Zileuton (Zyflo) in Combination With Imatinib Mesylate (Gleevec) in CML.

Chronic Myelogenous Leukemia

United States
Bayer

Completed

Open Label Phase II Study of BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (ORACLE)

Chronic Myelogenous Leukemia

United States, France

Clinical Trials on Leukemia, Chronic Myelogenous

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Burundi

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations